23 results on '"López-Campos, José Luis"'
Search Results
2. A Pilot Study on Proteomic Predictors of Mortality in Stable COPD.
- Author
-
Enríquez-Rodríguez, Cesar Jessé, Casadevall, Carme, Faner, Rosa, Pascual-Guardia, Sergi, Castro-Acosta, Ady, López-Campos, José Luis, Peces-Barba, Germán, Seijo, Luis, Caguana-Vélez, Oswaldo Antonio, Monsó, Eduard, Rodríguez-Chiaradia, Diego, Barreiro, Esther, Cosío, Borja G., Agustí, Alvar, Gea, Joaquim, and Group, on behalf of the BIOMEPOC
- Subjects
CHRONIC obstructive pulmonary disease ,PEPTIDE mass fingerprinting ,ARTIFICIAL intelligence ,PROTEOMICS ,DEATH forecasting - Abstract
Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of global mortality. Despite clinical predictors (age, severity, comorbidities, etc.) being established, proteomics offers comprehensive biological profiling to obtain deeper insights into COPD pathophysiology and survival prognoses. This pilot study aimed to identify proteomic footprints that could be potentially useful in predicting mortality in stable COPD patients. Plasma samples from 40 patients were subjected to both blind (liquid chromatography–mass spectrometry) and hypothesis-driven (multiplex immunoassays) proteomic analyses supported by artificial intelligence (AI) before a 4-year clinical follow-up. Among the 34 patients whose survival status was confirmed (mean age 69 ± 9 years, 29.5% women, FEV
1 42 ± 15.3% ref.), 32% were dead in the fourth year. The analysis identified 363 proteins/peptides, with 31 showing significant differences between the survivors and non-survivors. These proteins predominantly belonged to different aspects of the immune response (12 proteins), hemostasis (9), and proinflammatory cytokines (5). The predictive modeling achieved excellent accuracy for mortality (90%) but a weaker performance for days of survival (Q2 0.18), improving mildly with AI-mediated blind selection of proteins (accuracy of 95%, Q2 of 0.52). Further stratification by protein groups highlighted the predictive value for mortality of either hemostasis or pro-inflammatory markers alone (accuracies of 95 and 89%, respectively). Therefore, stable COPD patients' proteomic footprints can effectively forecast 4-year mortality, emphasizing the role of inflammatory, immune, and cardiovascular events. Future applications may enhance the prognostic precision and guide preventive interventions. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
3. Dysfunction in the Cystic Fibrosis Transmembrane Regulator in Chronic Obstructive Pulmonary Disease as a Potential Target for Personalised Medicine
- Author
-
Carrasco-Hernández, Laura, Quintana-Gallego, Esther, Calero, Carmen, Reinoso-Arija, Rocío, Ruiz-Duque, Borja, López-Campos, José Luis, [Carrasco-Hernández,L, Quintana-Gallego,E, Calero,C, Reinoso-Arija,R, Ruiz-Duque,B, López-Campos,JL] Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/Universidad de Sevilla, Sevilla, Spain. [Carrasco-Hernández,L, and López-Campos,JL] Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
- Subjects
Moco ,Inhibidores de fosfodiesterasa ,Icenticaftor ,Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Antioxidants [Medical Subject Headings] ,COPD ,Enfermedad pulmonar obstructiva crónica ,Diseases::Respiratory Tract Diseases::Lung Diseases::Lung Diseases, Obstructive::Pulmonary Disease, Chronic Obstructive [Medical Subject Headings] ,Mucociliary clearance ,Anatomy::Fluids and Secretions::Bodily Secretions::Mucus [Medical Subject Headings] ,Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Phosphodiesterase Inhibitors [Medical Subject Headings] ,Organisms::Bacteria [Medical Subject Headings] ,Inflammation ,Inflamación ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Protein S [Medical Subject Headings] ,Phenomena and Processes::Chemical Phenomena::Physicochemical Phenomena::Viscosity [Medical Subject Headings] ,Regulador de conductancia de transmembrana de fibrosis quística ,Organisms::Viruses [Medical Subject Headings] ,CFTR modulators ,Ivacaftor ,Mucus ,Depuración mucociliar ,Phosphodiesterase inhibitors ,Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Carrier Proteins::Membrane Transport Proteins::Ion Channels::Chloride Channels::Cystic Fibrosis Transmembrane Conductance Regulator [Medical Subject Headings] ,Cystic fibrosis transmembrane conductance regulator ,Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Inflammation [Medical Subject Headings] ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Techniques, Respiratory System::Mucociliary Clearance [Medical Subject Headings] ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Fluid Therapy [Medical Subject Headings] - Abstract
In recent years, numerous pathways were explored in the pathogenesis of COPD in the quest for new potential therapeutic targets for more personalised medical care. In this context, the study of the cystic fibrosis transmembrane conductance regulator (CFTR) began to gain importance, especially since the advent of the new CFTR modulators which had the potential to correct this protein's dysfunction in COPD. The CFTR is an ion transporter that regulates the hydration and viscosity of mucous secretions in the airway. Therefore, its abnormal function favours the accumulation of thicker and more viscous secretions, reduces the periciliary layer and mucociliary clearance, and produces inflammation in the airway, as a consequence of a bronchial infection by both bacteria and viruses. Identifying CFTR dysfunction in the context of COPD pathogenesis is key to fully understanding its role in the complex pathophysiology of COPD and the potential of the different therapeutic approaches proposed to overcome this dysfunction. In particular, the potential of the rehydration of mucus and the role of antioxidants and phosphodiesterase inhibitors should be discussed. Additionally, the modulatory drugs which enhance or restore decreased levels of the protein CFTR were recently described. In particular, two CFTR potentiators, ivacaftor and icenticaftor, were explored in COPD. The present review updated the pathophysiology of the complex role of CFTR in COPD and the therapeutic options which could be explored. Yes
- Published
- 2021
4. Actualización 2021 de la guía española de la EPOC (GesEPOC). Diagnóstico y tratamiento del síndrome de agudización de la EPOC
- Author
-
Soler-Cataluña, Juan José, Piñera, Pascual, Trigueros, Juan Antonio, Calle, Myriam, Casanova, Ciro, Cosío, Borja G, López-Campos, José Luis, Molina, Jesús, Almagro, Pere, Gómez, José-Tomás, Riesco, Juan Antonio, Simonet, Pere, Rigau, David, Soriano, Joan B, Ancochea, Julio, Miravitlles, Marc, and en representación del grupo de trabajo de GesEPOC 2021
- Subjects
Agudización ,Rasgos tratables ,COPD ,Exacerbation ,enfermedad pulmonar obstructiva crónica ,Syndrome ,Síndrome ,Treatable traits - Abstract
This article details the GesEPOC 2021 recommendations on the diagnosis and treatment of COPD exacerbation syndrome (CES). The guidelines propose a definition-based syndromic approach, a new classification of severity, and the recognition of different treatable traits (TT), representing a new step toward personalized medicine. The evidence is evaluated using GRADE methodology, with the incorporation of 6 new PICO questions. The diagnostic process comprises four stages: 1) establish a diagnosis of CES, 2) assess the severity of the episode, 3) identify the trigger, and 4) address TTs. This diagnostic process differentiates an outpatient approach, that recommends the inclusion of a basic battery of tests, from a more comprehensive hospital approach, that includes the study of different biomarkers and imaging tests. Bronchodilator treatment for immediate relief of symptoms is considered essential for all patients, while the use of antibiotics, systemic corticosteroids, oxygen therapy, and assisted ventilation and the treatment of comorbidities will vary depending on severity and possible TTs. The use of antibiotics will be indicated particularly if sputum color changes, when ventilatory assistance is required, in cases involving pneumonia, and in patients with elevated C-reactive protein (≥ 20 mg/L). Systemic corticosteroids are recommended in CES that requires admission and are suggested in moderate CES. These drugs are more effective in patients with blood eosinophil counts ≥ 300 cells/mm3. Acute-phase non-invasive mechanical ventilation is specified primarily for patients with CES who develop respiratory acidosis despite initial treatment.
- Published
- 2021
5. Inflammatory response in human lung cells stimulated with plasma from COPD patients.
- Author
-
Arellano-Orden, Elena, Calero-Acuña, Carmen, Sánchez-López, Verónica, Carrasco-Hernández, Laura, Márquez-Martín, Eduardo, Ortega-Ruiz, Francisco, Otero-Candelera, Remedios, Marín-Hinojosa, Carmen, and López-Campos, José Luis
- Subjects
BRONCHIECTASIS ,PLASMA cells ,CHRONIC obstructive pulmonary disease ,INFLAMMATION ,LUNGS ,FLUTICASONE ,CHRONIC bronchitis - Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a condition resulting from a persistent inflammatory state in the airways even after smoking cessation. Intriguingly, the reasons behind this persistence of the inflammatory influx without smoking exposure have not been fully unraveled. We aimed to explore the hypothesis that systemic inflammation in COPD patients influences lung cell inflammatory response. Methods:We cultured human lung fibroblast and human airway epithelial cell lines with plasma from COPD patients (four emphysematous-COPD, four asthma-COPD overlap, four chronic bronchitis-COPD, and four bronchiectasis-COPD), and four smokers or ex-smokers without COPD as controls. Non-stimulated cells were used as controls. We measured Interleukine-8 (IL-8), C-reactive protein (CRP) and matrix metalloproteinase-9 (MMP-9) in plasma and culture supernatants by ELISA. Results: Cells stimulated with plasma from COPD patients and non-COPD smoker subjects produced higher CRP, IL-8 and MMP-9 levels, an increase for COPD in CRP (p=0.029) in epithelial cells and IL-8 (p=0.039) in fibroblasts and decrease for MMP-9 (p=0.039) in fibroblasts, compared with non-stimulated cells. The response was higher in epithelial cells for IL-8 (p=0.003) and in fibroblasts for MMP-9 (p=0.063). The plasma from chronic bronchitis and bronchiectasis phenotypes induced higher IL-8 in fibroblasts. Conclusions: Plasma from COPD patients increases the inflammatory response in lung epithelial cells and lung fibroblasts, with a different response depending on the cell type and clinical phenotype. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Status of and strategies for improving adherence to COPD treatment
- Author
-
López-Campos, José Luis, Quintana Gallego, Esther, and Carrasco Hernández, Laura
- Subjects
Time Factors ,Nebulizers and Vaporizers ,Reminder Systems ,inhaled therapy ,Review ,Bronchodilator Agents ,Directly Observed Therapy ,Medication Adherence ,medication reminders ,Pulmonary Disease, Chronic Obstructive ,Treatment Outcome ,Adrenal Cortex Hormones ,Patient Satisfaction ,Risk Factors ,Administration, Inhalation ,COPD ,Humans ,adherence ,Drug Monitoring ,Lung - Abstract
Despite the wide application of adherence as a concept, the definition, evaluation and improvement of the adherence to treatment by patients with chronic obstructive pulmonary disease (COPD) still present some challenges. First, it is necessary to clearly define the concepts of treatment adherence, compliance and persistence. Second, it is critical to consider the various methods of evaluating and quantifying adherence when interpreting adherence studies. In addition, the advantages and disadvantages of the different ways of measuring treatment adherence should be taken into account. Another subject of some debate is the number of variables associated with COPD treatment adherence. Adherence is a complex concept that goes beyond the dosage or the use of inhalation devices, and a number of variables are involved in determining adherence, from the clinical aspects of the disease to the patient’s confidence in the doctor’s expertise and the level of social support experienced by the patient. Notably, despite these challenges, the importance of adherence has been well established by clinical trials and routine clinical practice. The available evidence consistently shows the substantial impact that a lack of adherence has on the control of the disease and its long-term prognosis. For these reasons, the correct evaluation of therapeutic adherence should be a key objective in clinical interviews of patients. In recent years, various initiatives for improving adherence have been explored. All these initiatives have been based on patient education. Therefore, health care professionals should be aware of the issues pertaining to adherence and take the opportunity to educate patients each time they contact the health care system.
- Published
- 2019
7. Natural Course of the Diffusing Capacity of the Lungs for Carbon Monoxide in COPD: Importance of Sex.
- Author
-
Casanova, Ciro, Gonzalez-Dávila, Enrique, Martínez-Gonzalez, Cristina, Cosio, Borja G., Fuster, Antonia, Feu, Nuria, Solanes, Ingrid, Cabrera, Carlos, Marin, José M., Balcells, Eva, Peces-Barba, Germán, de Torres, Juan P., Marín-Oto, Marta, Calle, Myriam, Golpe, Rafael, Ojeda, Elena, Divo, Miguel, Pinto-Plata, Victor, Amado, Carlos, and López-Campos, José Luis
- Subjects
CARBON monoxide ,LUNG volume measurements ,OBSTRUCTIVE lung diseases ,RESEARCH ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,SEX distribution ,COMPARATIVE studies ,PULMONARY function tests ,PULMONARY gas exchange ,PHENOTYPES - Abstract
Background: The value of the single-breath diffusing capacity of the lungs for carbon monoxide (Dlco) relates to outcomes for patients with COPD. However, little is known about the natural course of Dlco over time, intersubject variability, and factors that may influence Dlco progression.Research Question: What is the natural course of Dlco in patients with COPD over time, and which other factors, including sex differences, could influence this progression?Study Design and Methods: We phenotyped 602 smokers (women, 33%), of whom 506 (84%) had COPD and 96 (16%) had no airflow limitation. Lung function, including Dlco, was monitored annually over 5 years. A random coefficients model was used to evaluate Dlco changes over time.Results: The mean (± SE) yearly decline in Dlco % in patients with COPD was 1.34% ± 0.015%/y. This was steeper compared with non-COPD control subjects (0.04% ± 0.032%/y; P = .004). Sixteen percent of the patients with COPD, vs 4.3% of the control subjects, had a statistically significant Dlco % slope annual decline (4.14%/y). At baseline, women with COPD had lower Dlco values (11.37% ± 2.27%; P < .001) in spite of a higher FEV1 % than men. Compared with men, women with COPD had a steeper Dlco annual decline of 0.89% ± 0.42%/y (P = .039).Interpretation: Patients with COPD have an accelerated decline in Dlco compared with smokers without the disease. However, the decline is slow, and a testing interval of 3 to 4 years may be clinically informative. The lower and more rapid decline in Dlco values in women, compared with men, suggests a differential impact of sex in gas exchange function.Trial Registry: ClinicalTrials.gov; No.: NCT01122758; URL: www.clinicaltrials.gov. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
8. The clinical implications of triple therapy in fixed-dose combination in COPD: from the trial to the patient.
- Author
-
López-Campos, José Luis, Carrasco-Hernández, Laura, Román Rodríguez, Lucas, Quintana-Gallego, Esther, Carmona Bernal, Carmen, and Alcázar Navarrete, Bernardino
- Abstract
Copyright of Archivos de Bronconeumología (English Edition) is the property of Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2020
- Full Text
- View/download PDF
9. Ten Research Questions for Improving COPD Care in the Next Decade.
- Author
-
López-Campos, José Luis, Rodríguez, Diego A., Quintana-Gallego, Esther, Martínez-Llorens, Juana, Carrasco Hernández, Laura, and Barreiro, Esther
- Subjects
- *
CHRONIC care model , *ELECTRONIC cigarettes , *BIOTHERAPY , *RESEARCH & development , *INDIVIDUALIZED medicine - Abstract
With the 60th anniversary of the CIBA symposium, it is worth evaluating research questions that should be prioritized in the future. Coming research initiatives can be summarized in 10 main areas. (1) From epidemiology the impact of new forms of electronic cigarettes on prevalence and mortality of COPD will be sought. (2) The study of the disease endotypes and its relationship phenotypes will have to be unraveled in the next decade. (3) Diagnosis of COPD faces several challenges opening the possibility of a change in the definition of the disease itself. (4) Patients' classification and risk stratification will need to be clarified and reassessed. (5) The asthma-COPD overlap dilemma will have to be clarified and define whether both conditions represent one only chronic airway disease again. (6) Integrating comorbidities in COPD care will be key in a progressively ageing population to improve clinical care in a chronic care model. (7) Nonpharmacological management have areas for research including pulmonary rehabilitation and vaccines. (8) Improving physical activity should focus research because of the clear prognostic impact. (9). Pharmacological therapies present several challenges including efficacy and safety issues with current medications and the development of biological therapy. (10) The definition, identification, categorization and specific therapy of exacerbations will also be an area of research development. During the next decade, we have a window of opportunity to address these research questions that will put us on the path for precision medicine. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. What pulmonologists think about the asthma–COPD overlap syndrome
- Author
-
Miravitlles, Marc, Alcázar-Navarrete, Bernardino, Alvarez Gutiérrez, Francisco Javier, Bazús, Teresa, Calle Rubio, Myriam, Casanova, Ciro, Cisneros, Carolina, De Torres, Juan Pablo, Entrenas, Luis M., Esteban, Cristóbal, García-Sidro, Patricia, Cosio, Borja G.., Huerta, Arturo, Iriberri, Milagros, Izquierdo, José Luis, López Viña, Antolín, López-Campos, José Luis, Martínez-Moragón, Eva, Pérez de Llano, Luis, Perpiñá, Miguel, Ros, José Antonio, Serrano, José, Soler-Cataluña, Juan José, Torrego, Alfons, Urrutia, Isabel, Plaza, Vicente, Universitat Autònoma de Barcelona, [Miravitlles,M] Pneumology Department, Hospital Universitari Vall d´Hebron, Barcelona, Spain. [Miravitlles,M, López-Campos,L] CIBER de Enfermedades Respiratorias (CIBERES) Madrid, Spain. [Alcázar,B] Respiratory Department, Hospital de Alta Resolución de Loja, Granada, Spain. [Alvarez,FJ, López-Campos,L] Medical-Surgical Unit of Respiratory Diseases, Virgen del Rocio University Hospital, Biomedicine Institute of Seville (IbiS), Seville, Spain. [Bazús,T] Department of Pneumology, Hospital Universitario Central de Asturias, Ovido, Spain. [Calle,M] Department of Pneumology, Hospital Clínico San Carlos, Madrid, Spain. [Casanova,C] Department of Pneumology, Hospital Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain. [Cisneros,C] Department of Pneumology, Hospital Universitario de La Princesa/Instituto de Investigación Sanitaria (IIS-IP), Madrid, Spain. [De Torres,JP] Pulmonary Department, Clínica Universidad de Navarra, Pamplona, Spain. [Entrenas,LM] Department of Pneumology, Hospital Universitario Reina Sofía, Córdoba, Spain. [Esteban,C, Urrutia,I] Department of Pneumology, Hospital Galdakao-Usansolo, Galdakao, Spain. [García-Sidro,P] Department of Pneumology, Hospital Universitario de La Plana, Vila-Real, Spain. [Cosio,BC] Department of Pneumology, Hospital Universitario Son Espases IdISPa, Palma de Mallorca, Spain. [Huerta,A] Sección Urgencias Medicina - Neumología, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona, Spain. [Iriberri,M] Department of Pneumology, Hospital Universitario de Cruces, Bilbao, Spain. [Izquierdo,JL] Department of Pneumology, Hospital Universitario de Guadalajara, Guadalajara, Spain. [López-Viña,A] Department of Pneumology, Hospital Universitario Puerta del Hierro Majadahonda, Madrid, Spain. [Martínez-Moragón,E] Department of Pneumology, Hospital Universitario Dr. Peset, Valencia, Spain. [Pérez de Llano,L] Department of Pneumology, Hospital Universitario Lucus Augusti, Lugo, Spain. [Perpiñá,M] Department of Pneumology, Hospital Universitario y Politécnico La Fe, Valencia, Spain. [Ros,JA] Department of Pneumology, Hospital Clínico Universitario Virgen de la Arrinxaca, Murcia, Spain. [Serrano,J] Department of Pneumology, Hospital Comarcal de Inca, Inca, Spain. [Soler-Cataluña,JJ] Department of Pneumology, Hospital Arnau de Vilanova-Liria, Valencia, Spain. [Torrejo,A, Plaza,V] Department of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomédica Sant Pau (IIB Sant Pau), Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain., and Marc Miravitlles has received speaker fees from Almirall, Boehringer Ingelheim, Pfizer, AstraZeneca, Chiesi, Esteve, GlaxoSmithKline, Menarini, Grifols, and Novartis, and consulting fees from Almirall, Boehringer Ingelheim, Cipla, Pfizer, GlaxoSmithKline, Gebro Pharma, CLS Behring, MediImmune, Takeda, Teva, Novartis, and Grifols. Bernardino Alcázar reports personal fees from Novartis AG, Boehringer Ingelheim, GSK, Almirall, AstraZeneca, and grants and personal fees from Menarini. Teresa Bazús has received honoraria or funding for attending scientific meetings from GSK, Chiesi, and Teva. Ciro Casanova has received speaker fees from AstraZeneca, GSK, Novartis, and Almirall y Gebro Pharma and consulting fees from Almirall, Novartis, and GSK. Carolina Cisneros has received speaker or consulting fees from AstraZeneca, GSK, Boehringer Ingelheim, Novartis, Takeda, Vifor Pharma, Chiesi, Orion, and Mundipharma. Luis M Entrenas has in the last 3 years received honoraria for speaking at sponsored meetings from Alter, AstraZeneca, Boehringer Ingelheim, Chiesi, Esteve, Ferrer, GSK, Menarini, MSD, Mundipharma, Novartis, Pfizer, and Teva, as a consultant for Chiesi, Mundipharma, and Novartis, and has received funding/grant support for research projects from not-for-profit foundations, as well as Novartis. Patricia García-Sidro has received fees for scientific meetings, scientific advice, and participating in clinical studies or writing for publications from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Esteve, Ferrer, Gebro, GlaxoSmithKline, Menarini, MSD, Mundipharma, Novartis, Pfizer, Rovi, Takeda-Nycomed, and Teva. Borja G Cosio has in the last 3 years received honoraria for speaking at sponsored meetings from Chiesi, GSK, Boehringer Ingelheim, Novartis, and Pfizer, consultant fees from Pfizer, Chiesi, and GSK, travel grants from Boehringer Ingelheim, Novartis, and Chiesi, and received unrestricted funding/grant support for research projects from a variety of government agencies and not-for-profit foundations, as well as Boehringer Ingelheim, Chiesi, and Menarini. Arturo Huerta has received personal fees from GSK, Novartis, Takeda, Menarini, and Boehringer Ingelheim. José Luis Izquierdo reports personal fees for consulting and lectures from Almirall, AstraZeneca, Bayer, Boehringer Ingelheim, Takeda-Nycomed, Pfizer, and Menarini. Antolin López-Viña has in the last 3 years received honoraria for speaking at sponsored meetings from Chiesi, GSK, Boehringer Ingelheim, Novartis, and Pfizer, as a consultant for Pfizer, Boehringer Ingelheim, and Novartis, has received assistance to meet travel costs from Boehringer Ingelheim, Novartis, Teva, and Chiesi, and has received funding/grant support for research projects from a variety of government agencies and not-for-profit foundations, as well as Chiesi and Menarini. Eva Martínez-Moragón has in the last 3 years received honoraria for speaking at sponsored meetings from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mundipharma, Teva, and Pfizer. Luis Pérez de Llano has in the last 3 years received honoraria for speaking at sponsored meetings from AstraZeneca, Boehringer Ingelheim, Menarini, Chiesi, GlaxoSmithKline, Teva, Almirall, Mundipharma, Esteve, Novartis, and Pfizer, as a consultant for Mundipharma, Pfizer, Ferrer, and Novartis, has received assistance to meet travel costs from GSK and Novartis, and has received funding/grant support for research projects from SEPAR and SERGAS. Juan José Soler-Cataluña has received speaker fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Esteve, Ferrer, GSK, Merck, Menarini, Sharp & Dohme, Novartis, Takeda, and Pfizer, and consulting fees from Boehringer Ingelheim, GSK, AstraZeneca, Ferrer, Novartis, Almirall, Merck, Sharp & Dohme, and Takeda. Vicente Plaza has in the last 3 years received honoraria for speaking at sponsored meetings from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Mundipharma, and Pfizer, as a consultant for Mundipharma, Orion and Teva, received assistance to meet travel costs from Boehringer Ingelheim and Chiesi, and received funding/grant support for research projects from a variety of government agencies and not-for-profit foundations, as well as Chiesi, Menarini, and Merck. The authors report no other conflicts of interest in this work.
- Subjects
Male ,Health Knowledge, Attitudes, Practice ,Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Data Collection::Questionnaires [Medical Subject Headings] ,humanos ,Disciplines and Occupations::Health Occupations::Specialization [Medical Subject Headings] ,Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings] ,broncodilatadores ,Anti-asthmatic Agent ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,Pulmonary Disease, Chronic Obstructive ,Adrenal Cortex Hormones ,Risk Factors ,immune system diseases ,Surveys and Questionnaires ,Pulmonary medicine ,Pulmonary Medicine ,Enfermedad pulmonar obstructiva crónica ,Anti-Asthmatic Agents ,guidelines ,mediana edad ,Pulmonologists ,Original Research ,Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings] ,COPD ,education.field_of_study ,Smoking ,Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Respiratory System Agents::Anti-Asthmatic Agents::Bronchodilator Agents [Medical Subject Headings] ,Overlap syndrome ,General Medicine ,Middle Aged ,Prognosis ,actitud del personal sanitario ,consenso ,Bronchodilator Agents ,Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Epidemiologic Factors::Causality::Risk Factors [Medical Subject Headings] ,asma ,pronóstico ,Consenso ,Female ,Antiasmáticos ,antiasmáticos ,Specialization ,medicine.medical_specialty ,Consensus ,Attitude of Health Personnel ,Population ,Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Habits::Smoking [Medical Subject Headings] ,Check Tags::Male [Medical Subject Headings] ,Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Respiratory System Agents::Anti-Asthmatic Agents [Medical Subject Headings] ,Diseases::Respiratory Tract Diseases::Lung Diseases::Lung Diseases, Obstructive::Asthma [Medical Subject Headings] ,International Journal of Chronic Obstructive Pulmonary Disease ,Predictive Value of Tests ,medicine ,Diseases::Respiratory Tract Diseases::Lung Diseases::Lung Diseases, Obstructive::Pulmonary Disease, Chronic Obstructive [Medical Subject Headings] ,Humans ,factores de riesgo ,especialización ,survey ,Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Epidemiologic Research Design::Sensitivity and Specificity::Predictive Value of Tests [Medical Subject Headings] ,Asthma copd overlap ,Intensive care medicine ,education ,Adrenergic beta-2 Receptor Agonists ,Asma ,Corticoesteroides ,Asthma ,pruebas de valores predictivos ,Psychiatry and Psychology::Behavior and Behavior Mechanisms::Psychology, Social::Group Processes::Consensus [Medical Subject Headings] ,business.industry ,Disciplines and Occupations::Health Occupations::Medicine::Internal Medicine::Pulmonary Medicine [Medical Subject Headings] ,Chemicals and Drugs::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Adrenal Cortex Hormones [Medical Subject Headings] ,hábito de fumar ,asthma ,Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Neurotransmitter Agents::Adrenergic Agents::Adrenergic Agonists::Adrenergic beta-Agonists::Adrenergic beta-2 Receptor Agonists [Medical Subject Headings] ,medicine.disease ,agonistas de receptores adrenérgicos beta-2 ,Broncodilatadores ,Health Care::Health Care Quality, Access, and Evaluation::Delivery of Health Care::Attitude to Health::Health Knowledge, Attitudes, Practice [Medical Subject Headings] ,respiratory tract diseases ,medicina pulmonar ,Check Tags::Female [Medical Subject Headings] ,Spain ,Psychiatry and Psychology::Behavior and Behavior Mechanisms::Attitude::Attitude of Health Personnel [Medical Subject Headings] ,Physical therapy ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings] ,business ,hormonas de la corteza suprarrenal ,ACOS - Abstract
Background: Some patients with COPD may share characteristics of asthma; this is the so-called asthma-COPD overlap syndrome (ACOS). There are no universally accepted criteria for ACOS, and most treatments for asthma and COPD have not been adequately tested in this population. Materials and methods: We performed a survey among pulmonology specialists in asthma and COPD aimed at collecting their opinions about ACOS and their attitudes in regard to some case scenarios of ACOS patients. The participants answered a structured questionnaire and attended a face-to-face meeting with the Metaplan methodology to discuss different aspects of ACOS. Results: A total of 26 pulmonologists with a mean age of 49.7 years participated in the survey (13 specialists in asthma and 13 in COPD). Among these, 84.6% recognized the existence of ACOS and stated that a mean of 12.6% of their patients might have this syndrome. In addition, 80.8% agreed that the diagnostic criteria for ACOS are not yet well defined. The most frequently mentioned characteristics of ACOS were a history of asthma (88.5%), significant smoking exposure (73.1%), and postbronchodilator forced expiratory volume in 1 second/forced vital capacity,0.7 (69.2%). The most accepted diagnostic criteria were eosinophilia in sputum (80.8%), a very positive bronchodilator test (69.2%), and a history of asthma before 40 years of age (65.4%). Up to 96.2% agreed that first-line treatment for ACOS was the combination of a long-acting beta(2)-agonist and inhaled steroid, with a long-acting antimuscarinic agent (triple therapy) for severe ACOS. Conclusion: Most Spanish specialists in asthma and COPD agree that ACOS exists, but the diagnostic criteria are not yet well defined. A previous history of asthma, smoking, and not fully reversible airflow limitation are considered the main characteristics of ACOS, with the most accepted first-line treatment being long-acting beta(2)-agonist/inhaled corticosteroids., The authors want to thank Montserrat Falgueras, Maria Fontanals, Laura Molina, Rosa Palomino, and Sonia Pisa (GOC Networking, Barcelona, Spain) for their help in the organization of the study, data entry and analysis of the questionnaires, and the facilitation of the Metaplan session. This study was funded by Chiesi Spain.
- Published
- 2015
11. The BIOMEPOC Project: Personalized Biomarkers and Clinical Profiles in Chronic Obstructive Pulmonary Disease.
- Author
-
Gea, Joaquim, Pascual, Sergi, Castro-Acosta, Ady, Hernández-Carcereny, Carmen, Castelo, Robert, Márquez-Martín, Eduardo, Montón, Concepción, Palou, Alexandre, Faner, Rosa, Furlong, Laura I., Seijo, Luis, Sanz, Ferran, Torà, Montserrat, Vilaplana, Carles, Casadevall, Carme, López-Campos, José Luis, Monsó, Eduard, Peces-Barba, Germán, Cosío, Borja G., and Agustí, Alvar
- Abstract
Copyright of Archivos de Bronconeumología (English Edition) is the property of Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2019
- Full Text
- View/download PDF
12. Characteristics of COPD Patients Managed in Respiratory Medicine Departments in Spain, According to GOLD Groups and GesEPOC Clinical Phenotypes.
- Author
-
Izquierdo, José Luis, Miravitlles, Marc, Esquinas, Cristina, Pérez, Maite, Calle, Myriam, López Campos, José Luis, Rodríguez González-Moro, José Miguel, Casanova, Ciro, Esteban, Cristóbal, and de Lucas, Pilar
- Abstract
Copyright of Archivos de Bronconeumología (English Edition) is the property of Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2018
- Full Text
- View/download PDF
13. Occupational and Biomass Exposure in COPD: Results of a Cross-Sectional Analysis of the On-Sint Study.
- Author
-
López-Campos, José Luis, Fernández-Villar, Alberto, Calero-Acuña, Carmen, Represas-Represas, Cristina, López-Ramírez, Cecilia, Leiro Fernández, Virginia, and Casamor, Ricard
- Abstract
Copyright of Archivos de Bronconeumología (English Edition) is the property of Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2017
- Full Text
- View/download PDF
14. Factors associated with high healthcare resource utilisation among COPD patients.
- Author
-
García-Polo, Cayo, Alcázar-Navarrete, Bernardino, Ruiz-Iturriaga, Luis Alberto, Herrejón, Alberto, Ros-Lucas, José Antonio, García-Sidro, Patricia, Tirado-Conde, Gema, López-Campos, José Luis, Martínez-Rivera, Carlos, Costán-Galicia, Joaquin, Mayoralas-Alises, Sagrario, De Miguel-Díez, Javier, and Miravitlles, Marc
- Abstract
Summary: Background: Chronic obstructive pulmonary disease (COPD) places a huge economic burden on healthcare systems, especially patients with frequent exacerbations and co-morbidities. Objectives: To identify factors associated with high utilisation of healthcare resources in a population of patients with COPD. Method: We conducted an observational, cross-sectional, multicentre study with the aim of identifying the factors associated with high resource utilisation among patients with COPD. Sociodemographic and anthropometric characteristics of the study population, as well as data on health-related quality of life, respiratory symptoms, presence of anxiety and depression, physical activity and lung function were collected. We examined the relationship between these variables and high utilisation of healthcare resources, by performing a multivariate analysis based on a logistic regression model. Results: 115 patients (64 were high users of healthcare resources, and 51 control patients) from 13 hospitals were selected. Patients presenting high resource utilisation had worse FEV
1 , worse basal SpO2 , less distance walked in the 6-minute walk test, and increased dyspnoea. They also had a worse BODE index, worse scores in all dimensions of the EURO-QOL 5D and the LCADL scale, and displayed a higher prevalence of depression. Multivariate analysis yielded a statistically significant association between SpO2 , LCADL scores, serum fibrinogen values and total leukocyte count, and high healthcare resource utilisation. Conclusions: COPD patients who incur higher healthcare resource utilisation show reduced physical activity, increased respiratory failure and increased systemic inflammation. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
15. Spanish COPD Guidelines (GesEPOC): Pharmacological Treatment of Stable COPD.
- Author
-
Miravitlles, Marc, Soler-Cataluña, Juan José, Calle, Myriam, Molina, Jesús, Almagro, Pere, Quintano, José Antonio, Riesco, Juan Antonio, Trigueros, Juan Antonio, Piñera, Pascual, Simón, Adolfo, López-Campos, José Luis, Soriano, Joan B., and Ancochea, Julio
- Subjects
OBSTRUCTIVE lung disease treatment ,GUIDELINES ,DISEASE exacerbation ,PULMONARY emphysema ,DRUG therapy - Abstract
Copyright of Archivos de Bronconeumología (English Edition) is the property of Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2012
- Full Text
- View/download PDF
16. Factors Associated With Hospital Admission for Exacerbation of Chronic Obstructive Pulmonary Disease.
- Author
-
Alcázar, Bernardino, García-Polo, Cayo, Herrejón, Alberto, Ruiz, Luis Alberto, de Miguel, Javier, Ros, José Antonio, García-Sidro, Patricia, Tirado Conde, Gema, López-Campos, José Luis, Martínez, Carlos, Costán, Joaquin, Bonnin, Marc, Mayoralas, Sagrario, and Miravitlles, Marc
- Subjects
OBSTRUCTIVE lung diseases ,DISEASE exacerbation ,HOSPITAL care ,HOSPITAL emergency services ,MULTIVARIATE analysis ,REGRESSION analysis ,HOSPITAL admission & discharge - Abstract
Copyright of Archivos de Bronconeumología (English Edition) is the property of Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2012
- Full Text
- View/download PDF
17. Clinical Audit of Patients Admitted to Hospital in Spain due to Exacerbation of COPD (AUDIPOC Study): Method and Organisation.
- Author
-
Pozo-Rodríguez, Francisco, Álvarez, Carlos José, Castro-Acosta, Ady, Moreno, Carlos Melero, Capelastegui, Alberto, Esteban, Cristobal, Carcereny, Carmen Hernández, López-Campos, José Luis, Izquierdo Alonso, José Luís, Quílez, Antonio López, and Agustí, Alvar
- Subjects
MEDICAL audit ,HOSPITAL admission & discharge ,OBSTRUCTIVE lung diseases patients ,DISEASE exacerbation ,MORTALITY - Abstract
Copyright of Archivos de Bronconeumología (English Edition) is the property of Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2010
- Full Text
- View/download PDF
18. Management Challenges in Chronic Obstructive Pulmonary Disease in the COVID-19 Pandemic: Telehealth and Virtual Reality.
- Author
-
Rutkowski, Sebastian and López-Campos, José Luis
- Subjects
- *
COVID-19 pandemic , *OBSTRUCTIVE lung diseases , *COVID-19 , *VIRTUAL reality , *TELEMEDICINE - Abstract
For the treatment of chronic obstructive pulmonary disease (COPD), early diagnosis and unconditionally correct management at the initial stage of the disease are very important when the symptoms are not yet too worrying. In this way, the progress of the disease can be slowed down, as can the occurrence of late, life-threatening symptoms. Pulmonary rehabilitation is an essential component of the management of COPD. The selection of appropriate exercises, which are determined during the classification of patients into a suitable improvement program, is of key importance in the process of rehabilitation. The coronavirus disease 2019 (COVID-19) pandemic has resulted in major limitations to public health care. Health systems were largely unprepared for an outbreak of this magnitude. Searching for new, attractive technologies that help patients with chronic diseases seems to be justified. This may be driven by telehealth platforms, likewise with the use of virtual reality (VR). Analysis of the available literature indicates promising effectiveness, high patient acceptance, and high motivations to undertake physical activity with the use of such a solution. Thus, the management of patients with COPD during the COVID-19 pandemic should include options for remote delivery of pulmonary rehabilitation, including home-based, telerehabilitation, and computer-based virtual programs. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. Four Decades of COPD Mortality Trends: Analysis of Trends and Multiple Causes of Death.
- Author
-
Fernández-García, Alberto, Pérez-Ríos, Mónica, Fernández-Villar, Alberto, Naveira, Gael, Candal-Pedreira, Cristina, Santiago-Pérez, María Isolina, Represas-Represas, Cristina, Malvar-Pintos, Alberto, Cerdeira-Caramés, Sara, Ruano-Raviña, Alberto, and López-Campos, José Luis
- Subjects
TREND analysis ,CAUSES of death ,OBSTRUCTIVE lung diseases ,MORTALITY - Abstract
There is little information on chronic obstructive pulmonary disease (COPD) mortality trends, age of death, or male:female ratio. This study therefore sought to analyze time trends in mortality with COPD recorded as the underlying cause of death from 1980 through 2017, and with COPD recorded other than as the underlying cause of death. We conducted an analysis of COPD deaths in Galicia (Spain) from 1980 through 2017, including those in which COPD was recorded other than as the underlying cause of death from 2015 through 2017. We calculated the crude and standardized rates, and analyzed mortality trends using joinpoint regression models. There were 43,234 COPD deaths, with a male:female ratio of 2.4. Median age of death was 82 years. A change point in the mortality trend was detected in 1996 with a significant decrease across the sexes, reflected by an annual percentage change of −3.8%. Taking deaths into account in which COPD participated or contributed without being the underlying cause led to an overall 42% increase in the mortality burden. The most frequent causes of death when COPD was not considered to be the underlying cause were bronchopulmonary neoplasms and cardiovascular diseases. COPD mortality has decreased steadily across the sexes in Galicia since 1996, and age of death has also gradually increased. Multiple-cause death analysis may help prevent the underestimation of COPD mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. Effectiveness of Non-Presential Individualized Exercise Training PrOgram (NIETO) in Lower Limb Physical Performance in Advanced COPD.
- Author
-
Sánchez-Nieto, Juan Miguel, Fernández-Muñoz, Irene, Carrillo-Alcaraz, Andrés, Bernabeu-Mora, Roberto, and López-Campos, José Luis
- Subjects
PHYSICAL mobility ,OBSTRUCTIVE lung diseases ,QUADRICEPS muscle ,MUSCLE strength - Abstract
Muscle training, a component of pulmonary rehabilitation (PR), improves the physical performance of patients with chronic obstructive pulmonary disease (COPD). Despite the existing evidence, the traditional center-based PR model is applied to a small percentage of patients and presents numerous problems of accessibility, adherence, and costs. This study presents a home model of simple muscle training, non-presential, monitored by telephone and individualized, according to the severity of the COPD. In addition, to evaluate the results, simple tests associated with the physical performance of the lower limbs, previously validated in COPD, have been used, such as the four-meter walk, speed test (4MGS) and the five-repetition test sitting and standing (5STS). The objective was to evaluate whether the Individualized Non-Presential Exercise Training PrOgram (NIETO) induces improvements in the 4MGS, 5STS and quadriceps muscle strength (QMS) tests in outpatients with advanced COPD (FEV1 ≤ 50%). After one year, the QMS was significantly higher in the intervention group (IG) than in the control group (CG) (2.44 ± 4.07 vs. 0.05 ± 4.26 kg; p = 0.009). The 4MGS and 5STS tests were significantly shorter in IG than in CG (−0.39 ± 0.86 vs. 0.37 ± 0.96 s; p = 0.001) and (−1.55 ± 2.83 vs. 0.60 ± 2.06 s; p = 0.001), respectively. A home model of simple muscle training monitored by telephone such as NIETO, can improve 4MGS, 5STS, and quadriceps strength tests in outpatients with advanced COPD. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
21. Sex Differences in the Effects of COPD on Incidence and Outcomes of Patients Hospitalized with ST and Non-ST Elevation Myocardial Infarction: A Population-Based Matched-Pair Analysis in Spain (2016–2018).
- Author
-
de-Miguel-Diez, Javier, Jiménez-García, Rodrigo, Hernandez-Barrera, Valentín, Ji, Zichen, de Miguel-Yanes, José María, López-Herranz, Marta, López-de-Andrés, Ana, and López-Campos, José Luis
- Subjects
OBSTRUCTIVE lung diseases - Abstract
We aimed to compare the incidence, clinical characteristics, and outcomes of patients admitted with myocardial infarction (MI), whether ST elevation MI (STEMI) or non-ST elevation MI (NSTEMI), according to the presence of chronic obstructive pulmonary disease (COPD), and to identify variables associated with in-hospital mortality (IHM). We selected all patients with MI (aged ≥40 years) included in the Spanish National Hospital Discharge Database (2016–2018). We matched each patient suffering COPD with a non-COPD patient with identical age, sex, type of MI, and year of hospitalization. We identified 109,759 men and 44,589 women with MI. The MI incidence was higher in COPD patients (incident rate ratio (IRR) 1.32; 95% confidence interval (CI) 1.29–1.35). Men with COPD had higher incidence of STEMI and NSTEMI than women with COPD. After matching, COPD men had a higher IHM than non-COPD men, but no differences were found among women. The probability of dying was higher among COPD men with STEMI in comparison with NSTEMI (odds ratio (OR) 2.33; 95% CI 1.96–2.77), with this risk being higher among COPD women (OR 2.63; 95% CI 1.75–3.95). Suffering COPD increased the IHM after an MI in men (OR 1.14; 95% CI 1.03–1.27), but no differences were found in women. COPD women had a higher IHM than men (OR 1.19; 95% CI 1.01–1.39). We conclude that MI incidence was higher in COPD patients. IHM was higher in COPD men than in those without COPD, but no differences were found among women. Among COPD patients, STEMI was more lethal than NSTEMI. Suffering COPD increased the IHM after MI among men. Women with COPD had a significantly higher probability of dying in the hospital than COPD men. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
22. Nocturnal Hypoxemia and CT Determined Pulmonary Artery Enlargement in Smokers.
- Author
-
Marin-Oto, Marta, Seijo, Luis M., Divo, Miguel, Bastarrika, Gorka, Ezponda, Ana, Calvo, Marta, Zulueta, Javier J., Gallardo, Guillermo, Cabezas, Elena, Peces-Barba, German, Pérez-Warnisher, Maria T., Marín, Jose M., Celli, Bartolomé R., Casanova, Ciro, De-Torres, Juan P., and López-Campos, José Luis
- Subjects
PULMONARY artery ,OBSTRUCTIVE lung diseases ,COMPUTED tomography ,HYPOXEMIA ,SLEEP apnea syndromes - Abstract
Background: Pulmonary artery enlargement (PAE) detected using chest computed tomography (CT) is associated with poor outcomes in chronic obstructive pulmonary disease (COPD). It is unknown whether nocturnal hypoxemia occurring in smokers, with or without COPD, obstructive sleep apnoea (OSA) or their overlap, may be associated with PAE assessed by chest CT. Methods: We analysed data from two prospective cohort studies that enrolled 284 smokers in lung cancer screening programs and completing baseline home sleep studies and chest CT scans. Main pulmonary artery diameter (PAD) and the ratio of the PAD to that of the aorta (PA:Ao ratio) were measured. PAE was defined as a PAD ≥ 29 mm in men and ≥27 mm in women or as a PA:Ao ratio > 0.9. We evaluated the association of PAE with baseline characteristics using multivariate logistic models. Results: PAE prevalence was 27% as defined by PAD measurements and 11.6% by the PA:Ao ratio. A body mass index ≥ 30 kg/m
2 (OR 2.01; 95%CI 1.06–3.78), lower % predicted of forced expiratory volume in one second (FEV1 ) (OR 1.03; 95%CI 1.02–1.05) and higher % of sleep time with O2 saturation < 90% (T90) (OR 1.02; 95%CI 1.00–1.03), were associated with PAE as determined by PAD. However, only T90 remained significantly associated with PAE as defined by the PA:Ao ratio (OR 1.02; 95%CI 1.01–1.03). In the subset group without OSA, only T90 remains associated with PAE, whether defined by PAD measurement (OR 1.02; 95%CI 1.01–1.03) or PA:Ao ratio (OR 1.04; 95%CI 1.01–1.07). Conclusions: In smokers with or without COPD, nocturnal hypoxemia was associated with PAE independently of OSA coexistence. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
23. Evaluation of Suboptimal Peak Inspiratory Flow in Patients with Stable COPD.
- Author
-
Represas-Represas, Cristina, Aballe-Santos, Luz, Fernández-García, Alberto, Priegue-Carrera, Ana, López-Campos, José-Luis, González-Montaos, Almudena, Botana-Rial, Maribel, and Fernández-Villar, Alberto
- Subjects
OBSTRUCTIVE lung diseases ,PATIENT compliance ,PATIENT satisfaction ,PATIENT selection - Abstract
Objective: Although the importance of assessing inspiratory flow in the selection of treatments for chronic obstructive pulmonary disease (COPD) is understood, evaluation of this factor is not yet widespread or standardized. The objective of the present work was to evaluate the peak inspiratory flow (PIF) of patients with COPD and to explore the variables associated with a suboptimal PIF. Methods: An observational, cross-sectional study was carried out at specialized nursing consultations over a period of 6 months. We collected clinical data as well as data on symptoms, treatment adherence, and patient satisfaction with their inhalers via questionnaires. PIF was determined using the In-Check Dial G16
® device (Clement Clarke International, Ltd., Harlow, UK). In each case, the PIF was considered suboptimal when it was off-target for any of the prescribed inhalers. The association with suboptimal PIF was evaluated using multivariate logistic regression and the results were expressed as the odds ratio (OR) with 95% confidence interval (CI). Results: A total of 122 COPD patients were included in this study, of whom 34 (27.9%) had suboptimal PIF. A total of 229 inhalers were tested, of which 186 (81.2%) were dry powder devices. The multivariate analysis found an association between suboptimal PIF and age (OR = 1.072; 95% CI (1.019, 1.128); p = 0.007) and forced vital capacity (OR = 0.961; 95% CI (0.933, 0.989); p = 0.006). Conclusions: About a third of patients in complex specialized COPD care have suboptimal PIFs, which is related to age and forced vital capacity. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.